Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

November 2023

Effets d'un traitement d'un an par le tofacitinib sur les biomarqueurs angiogéniques dans la polyarthrite rhumatoïde

Rheumatology (Oxford) 2023; 62(SI3):SI304–SI312 doi 10.1093/rheumatology/kead502

Hamar A,

Tajti G,

Végh E,

Soós B,

Panyi G,

Seres T,

Szűcs G,

Szekanecz Z

This study by Kerekes, et al. investigated the relationship between tofacitinib therapy, angiogenic biomarker levels, and vascular inflammation and function in RA patients. The authors found that tofacitinib treatment reduced the production of bFGF, PlGF and IL-6, which may inhibit synovial and aortic inflammation.

Keywords:

Tofacitinib

August 2023

Le filgotinib modifie les biomarqueurs des protéines du sang périphérique associés à l'inflammation chez les adultes atteints de polyarthrite rhumatoïde active et avec réponse inadéquate antérieure au méthotrexate

Rheumatol Ther. 2023;10(5):1335–1348 doi 10.1007/s40744-023-00583-9

Tanaka Y,

Taylor PC,

Elboudwarej E,

Hertz A,

Shao X,

Emoto K,

This study by Tanaka, et al. shows that filgotinib reduces peripheral protein biomarkers associated with JAK/STAT signalling, inflammatory signalling, immune cell migration, and bone resorption in RA patients. Notably, filgotinib 200 mg significantly reduced IL-6, TNF, CXCL13 levels as early as Week 4.